Maria de Lourdes de Abreu Ferrari

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 208 citations

Systemic Treatment, Golimumab Monotherapy, Gastroenterology +4

Influence of<i>Saccharomyces boulardii</i>on the intestinal permeability of patients with Crohn's disease in remission

Eduardo García Vilela, Maria de Lourdes de Abreu Ferrari, Henrique Oswaldo da Gama Tôrres et al. · Scandinavian Journal of Gastroenterology · 2008 · 178 citations

Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn’s disease

Francisco Guilherme Cancela e Penna, Rodrigo Macedo Rosa, Pedro Ferrari Sales Cunha et al. · BMC Gastroenterology · 2020 · 32 citations · Full text

Changes in Intestinal Permeability after Roux-en-Y Gastric Bypass

Alexandre Lages Savassi-Rocha, Marco Túlio Costa Diniz, Eduardo García Vilela et al. · Obesity Surgery · 2013 · 30 citations

Roux-en-y Gastric Bypass, Gastroenterology, Gastric Bypass +3

Intestinal Permeability and Antigliadin Antibody Test for Monitoring Adult Patients with Celiac Disease

Eduardo García Vilela, Maria de Lourdes de Abreu Ferrari, Henrique Osvaldo de Gama Torres et al. · Digestive Diseases and Sciences · 2007 · 28 citations

Intestinal Permeability, Food Intolerance, Autoimmune Disease +10